Young M, Jackson-Spence F, Beltran L, Day E, Suarez C, Bex A, et al. Renal cell carcinoma. Lancet. 2024;404:476–91.
Google Scholar
Cotta BH, Choueiri TK, Cieslik M, Ghatalia P, Mehra R, Morgan TM, et al. Current landscape of genomic biomarkers in clear cell renal cell carcinoma. Eur Urol. 2023;84:166–75.
Google Scholar
Ghoreifi A, Vaishampayan U, Yin M, Psutka SP, Djaladat H. Immune checkpoint inhibitor therapy before nephrectomy for locally advanced and metastatic renal cell carcinoma: a review. JAMA Oncol. 2024;10:240–8.
Google Scholar
Ryan CW, Tangen CM, Heath EI, Stein MN, Meng MV, Alva AS, et al. Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2023;402:1043–51.
Google Scholar
Motzer RJ, Jonasch E, Agarwal N, Alva A, Bagshaw H, Baine M, et al. NCCN guidelines(R) insights: kidney cancer, version 2. J Natl Compr Canc Netw 2024. 2024;22:4–16.
Google Scholar
Jin J, Xie Y, Zhang JS, Wang JQ, Dai SJ, He WF, et al. Sunitinib resistance in renal cell carcinoma: from molecular mechanisms to predictive biomarkers. Drug Resist Updat. 2023;67:100929.
Google Scholar
Yu H, Lin L, Zhang Z, Zhang H, Hu H. Targeting NF-kappaB pathway for the therapy of diseases: mechanism and clinical study. Signal Transduct Target Ther. 2020;5:209.
Google Scholar
Zhang T, Ma C, Zhang Z, Zhang H, Hu H. NF-KappaB signaling in inflammation and cancer. MedComm. 2021;2:618–53.
Google Scholar
Tanaka K, Yu HA, Yang S, Han S, Selcuklu SD, Kim K, et al. Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis. Cancer Cell. 2021;39:1245–61.
Google Scholar
Li Z, Ning K, Zhao D, Zhou Z, Zhao J, Long X, et al. Targeting the metabolic enzyme PGAM2 overcomes enzalutamide resistance in castration-resistant prostate cancer by inhibiting BCL2 signaling. Cancer Res. 2023;83:3753–66.
Google Scholar
Hata AN, Niederst MJ, Archibald HL, Gomez-Caraballo M, Siddiqui FM, Mulvey HE, et al. Tumour cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat Med. 2016;22:262–9.
Google Scholar
Collins PE, Mitxitorena I, Carmody RJ The ubiquitination of NF-kappaB subunits in the control of transcription. Cells. 2016;5:23.
Ren C, Han X, Lu C, Yang T, Qiao P, Sun Y, et al. Ubiquitination of NF-kappaB p65 by FBXW2 suppresses breast cancer stemness, tumourigenesis, and paclitaxel resistance. Cell Death Differ. 2022;29:381–92.
Google Scholar
Cong M, Wang Y, Yang Y, Lian C, Zhuang X, Li X, et al. MTSS1 suppresses mammary tumour-initiating cells by enhancing RBCK1-mediated p65 ubiquitination. Nat Cancer. 2020;1:222–34.
Google Scholar
Higa LA, Wu M, Ye T, Kobayashi R, Sun H, Zhang H. CUL4-DDB1 ubiquitin ligase interacts with multiple WD40-repeat proteins and regulates histone methylation. Nat Cell Biol. 2006;8:1277–83.
Google Scholar
Green DR The death receptor pathway of apoptosis. Cold Spring Harb Perspect Biol. 2022;14:a041053.
Deng Q, Chen L, Zhang G, Liu L, Luo SM, Gao X. TRIAL-based combination therapies in cancers. Int Immunopharmacol. 2024;138:112570.
Google Scholar
Oh YT, Sun SY Regulation of cancer metastasis by TRAIL/death receptor signaling. Biomolecules. 2021;11:499.
Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity. 1997;7:821–30.
Google Scholar
Hu WH, Johnson H, Shu HB. Tumour necrosis factor-related apoptosis-inducing ligand receptors signal NF-kappaB and JNK activation and apoptosis through distinct pathways. J Biol Chem. 1999;274:30603–10.
Google Scholar
von Karstedt S, Conti A, Nobis M, Montinaro A, Hartwig T, Lemke J, et al. Cancer cell-autonomous TRAIL-R signaling promotes KRAS-driven cancer progression, invasion, and metastasis. Cancer Cell. 2015;27:561–73.
Google Scholar
Zhang S, Chen Z, Shi P, Fan S, He Y, Wang Q, et al. Downregulation of death receptor 4 is tightly associated with positive response of EGFR mutant lung cancer to EGFR-targeted therapy and improved prognosis. Theranostics. 2021;11:3964–80.
Google Scholar
Xiong Z, Yuan C, Shi J, Xiong W, Huang Y, Xiao W, et al. Restoring the epigenetically silenced PCK2 suppresses renal cell carcinoma progression and increases sensitivity to sunitinib by promoting endoplasmic reticulum stress. Theranostics. 2020;10:11444–61.
Google Scholar
Pan Y, Lu X, Shu G, Cen J, Lu J, Zhou M, et al. Extracellular vesicle-mediated transfer of LncRNA IGFL2-AS1 confers sunitinib resistance in renal cell carcinoma. Cancer Res. 2023;83:103–16.
Google Scholar
Tao W, Wang BY, Luo L, Li Q, Meng ZA, Xia TL, et al. A urine extracellular vesicle lncRNA classifier for high-grade prostate cancer and increased risk of progression: a multi-center study. Cell Rep Med. 2023;4:101240.
Google Scholar
Zhang L, Wang X, Bullock AJ, Callea M, Shah H, Song J, et al. Anti-S1P antibody as a novel therapeutic strategy for VEGFR TKI-resistant renal cancer. Clin Cancer Res. 2015;21:1925–34.
Google Scholar
Wang H, Xiong A, Chen X, Guo J, Tang Z, Wu C, et al. CXCR1(+) neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer. Signal Transduct Target Ther. 2024;9:342.
Google Scholar
Zhu Y, Liu H, Xu L, An H, Liu W, Liu Y, et al. p21-activated kinase 1 determines stem-like phenotype and sunitinib resistance via NF-kappaB/IL-6 activation in renal cell carcinoma. Cell Death Dis. 2015;6:e1637.
Google Scholar
Liu J, Liu K, Wang Y, Shi Z, Xu R, Zhang Y, et al. Death receptor 5 is required for intestinal stem cell activity during intestinal epithelial renewal at homoeostasis. Cell Death Dis. 2024;15:27.
Google Scholar
Li S, Lv J, Li Z, Zhang Q, Lu J, Huo X, et al. Overcoming multi-drug resistance in SCLC: a synergistic approach with venetoclax and hydroxychloroquine targeting the lncRNA LYPLAL1-DT/BCL2/BECN1 pathway. Mol Cancer. 2024;23:243.
Google Scholar
Wang L, Jin H, Jochems F, Wang S, Lieftink C, Martinez IM, et al. cFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysis. Nat Cancer. 2022;3:1284–99.
Google Scholar
Zhang J, Wu T, Simon J, Takada M, Saito R, Fan C, et al. VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Science. 2018;361:290–5.
Google Scholar
Sanchez A, Tripathy D, Yin X, Luo J, Martinez JM, Grammas P. Sunitinib enhances neuronal survival in vitro via NF-kappaB-mediated signaling and expression of cyclooxygenase-2 and inducible nitric oxide synthase. J Neuroinflamm. 2013;10:93.
Google Scholar
Giuliano S, Dufies M, Ndiaye PD, Viotti J, Borchiellini D, Parola J, et al. Resistance to lysosomotropic drugs used to treat kidney and breast cancers involves autophagy and inflammation and converges in inducing CXCL5. Theranostics. 2019;9:1181–99.
Google Scholar
Zeng X, Chen Z, Zhu Y, Liu L, Zhang Z, Xiao Y, et al. O-GlcNAcylation regulation of RIPK1-dependent apoptosis dictates sensitivity to sunitinib in renal cell carcinoma. Drug Resist Updat. 2024;77:101150.
Google Scholar
Wen S, Huang X, Xiong L, Zeng H, Wu S, An K, et al. WDR12/RAC1 axis promoted proliferation and anti-apoptosis in colorectal cancer cells. Mol Cell Biochem. 2024;479:3341–54.
Google Scholar
Li JL, Chen C, Chen W, Zhao LF, Xu XK, Li Y, et al. Integrative genomic analyses identify WDR12 as a novel oncogene involved in glioblastoma. J Cell Physiol. 2020;235:7344–55.
Google Scholar
Powles T, Plimack ER, Soulieres D, Waddell T, Stus V, Gafanov R, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol. 2020;21:1563–73.
Google Scholar
Yang Y, Li S, Wang Y, Zhao Y, Li Q. Protein tyrosine kinase inhibitor resistance in malignant tumours: molecular mechanisms and future perspective. Signal Transduct Target Ther. 2022;7:329.
Google Scholar
Cruz-Gordillo P, Honeywell ME, Harper NW, Leete T, Lee MJ ELP-dependent expression of MCL1 promotes resistance to EGFR inhibition in triple-negative breast cancer cells. Sci Signal. 2020;13:9820.
Apicella M, Giannoni E, Fiore S, Ferrari KJ, Fernandez-Perez D, Isella C, et al. Increased lactate secretion by cancer cells sustains non-cell-autonomous adaptive resistance to MET and EGFR targeted therapies. Cell Metab. 2018;28:848–65.
Google Scholar
Jeong WJ, Park JC, Kim WS, Ro EJ, Jeon SH, Lee SK, et al. WDR76 is a RAS binding protein that functions as a tumour suppressor via RAS degradation. Nat Commun. 2019;10:295.
Google Scholar
Zhang H, Chen G, Feng X, Song H, Meng L, Fu Y, et al. Targeting WDxR motif reprograms immune microenvironment and inhibits hepatocellular carcinoma progression. EMBO Mol Med. 2023;15:e15924.
Google Scholar
Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 2020;17:395–417.
Google Scholar
Deng D, Shah K. TRAIL of hope meeting resistance in cancer. Trends Cancer. 2020;6:989–1001.
Google Scholar
Shrader M, Pino MS, Lashinger L, Bar-Eli M, Adam L, Dinney CP, et al. Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression. Cancer Res. 2007;67:1430–5.
Google Scholar
Correction: The Multikinase Inhibitor Sorafenib Potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res. 2018;78:1575.
Ding W, Cai T, Zhu H, Wu R, Tu C, Yang L, et al. Synergistic antitumour effect of TRAIL in combination with sunitinib in vitro and in vivo. Cancer Lett. 2010;293:158–66.
Google Scholar
Mahalingam D, Carew JS, Espitia CM, Cool RH, Giles FJ, de Jong S, et al. Heightened JNK activation and reduced XIAP levels promote TRAIL and sunitinib-mediated apoptosis in colon cancer models. Cancers. 2019;11:895.
Shadman M. Diagnosis and treatment of chronic lymphocytic leukemia: a review. JAMA. 2023;329:918–32.
Google Scholar
DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617–29.
Google Scholar
Oppermann S, Ylanko J, Shi Y, Hariharan S, Oakes CC, Brauer PM, et al. High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells. Blood. 2016;128:934–47.
Google Scholar
Tang Y, Song T, Gao L, Mao F. Venetoclax synergizes sunitinib in renal cell carcincoma through inhibition of BCL-2. Anticancer Agents Med Chem. 2023;23:2027–34.
Google Scholar
